BioReference Laboratories
While reform of lab-developed test regulations and PAMA appeared possible at the beginning of 2022, in the end, the status quo won out.
The firm alleges its competitors infringe its patents describing processes for finding chromosomal abnormalities in fetal cell-free DNA.
Aspira Women's Health, BioReference Ink Distribution Deal for Ovarian Cancer Test
The Ova1Plus test combines two FDA-approved assays that analyze levels of five biomarkers to provide a malignancy risk index.
Even as layoffs hit labs due to declining demand for COVID-19 testing, a wave of departing workers and a depleted trainee pipeline make personnel hard to come by.
BioReference to Pay $10M to Resolve State, Federal Lab Fraud Case
The company was accused of disguising kickbacks as rental payments to encourage referrals for laboratory testing from high-volume doctor groups.
Oct 28, 2021
Opko Health Q3 Revenues Fall 10 Percent
Sep 2, 2021
May 6, 2021
Apr 29, 2021
Apr 7, 2021